PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry

Polycomb repressive complex 2 (PRC2) has oncogenic and tumor-suppressive roles in cancer. There is clinical success of targeting this complex in PRC2-dependent cancers, but an unmet therapeutic need exists in PRC2-loss cancer. PRC2-inactivating mutations are a hallmark feature of high-grade malignan...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Amish J., Warda, Sarah, Maag, Jesper L.V., Misra, Rohan, Miranda-Román, Miguel A., Pachai, Mohini R., Lee, Cindy J., Li, Dan, Wang, Naitao, Bayshtok, Gabriella, Fishinevich, Eve, Meng, Yinuo, Wong, Elissa W.P., Yan, Juan, Giff, Emily, Pappalardi, Melissa B., McCabe, Michael T., Fletcher, Jonathan A., Rudin, Charles M., Chandarlapaty, Sarat, Scandura, Joseph M., Koche, Richard P., Glass, Jacob L., Antonescu, Cristina R., Zheng, Deyou, Chen, Yu, Chi, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437570/
https://www.ncbi.nlm.nih.gov/pubmed/35789380
http://dx.doi.org/10.1158/2159-8290.CD-21-1671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437570/
https://www.ncbi.nlm.nih.gov/pubmed/35789380
http://dx.doi.org/10.1158/2159-8290.CD-21-1671

Ejemplares similares